Comparison between the antiemetic effects of palonosetron and granisetron in breast cancer patients treated with anthracycline‑based regimens

Ohzawa,Hideyuki; Miki,Atsushi; Hozumi,Yasuo; Miyazaki,Chieko; Sagara,Yuka; Tanaka,Yumiko; Shiba,Satomi; Joutoku,Hiromi; Sakuragi,Masako; Takehara,Megumi; Sakuma,Yasunaru; Nishimura,Wataru; Fujii,Hirofumi; Yasuda,Yoshikazu

doi:10.3892/ol.2014.2640

January-2015 Volume 9 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-2015 Volume 9 Issue 1

Full Size Image

Article

Comparison between the antiemetic effects of palonosetron and granisetron in breast cancer patients treated with anthracycline‑based regimens

Authors:
- Hideyuki Ohzawa
- Atsushi Miki
- Yasuo Hozumi
- Chieko Miyazaki
- Yuka Sagara
- Yumiko Tanaka
- Satomi Shiba
- Hiromi Joutoku
- Masako Sakuragi
- Megumi Takehara
- Yasunaru Sakuma
- Wataru Nishimura
- Hirofumi Fujii
- Yoshikazu Yasuda
View Affiliations / Copyright

Affiliations: Department of Breast Surgery, Jichi Medical University, Shimotsuke City, Tochigi 329‑0498, Japan, Department of Gastrointestinal Surgery, Jichi Medical University, Shimotsuke City, Tochigi 329‑0498, Japan, Department of Metabolic Disorder, Diabetes Research Center, National Center for Global Health and Medicine, Shinjuku‑ku, Tokyo 162‑8655, Japan, Department of Clinical Oncology, Jichi Medical University, Shimotsuke City, Tochigi 329‑0498, Japan
Pages: 119-124
|
Published online on: October 24, 2014

https://doi.org/10.3892/ol.2014.2640
Expand metrics +

Abstract

Chemotherapy‑induced nausea and vomiting is a serious adverse side‑effect of anthracycline‑based chemotherapy regimens, in patients with breast cancer. A combination of three drugs, 5‑hydroxytryptamine (5‑HT3) receptor antagonist, aprepitant and dexamethasone, is recommended for antiemetic therapy. Palonosetron (PALO), a novel 5‑HT3 receptor antagonist has been identified to be effective against delayed nausea and vomiting. In this study, the results of PALO for patients who received anthracycline‑based chemotherapy were compared with that of granisetron (GRA) using a crossover study design. This study evaluated the efficacy of antiemetics in the first cycle of chemotherapy, as well as the second and third cycles. A total of 21 patients and 19 patients were assigned to PALO and GRA treatment groups during the first cycle of chemotherapy, respectively. The patients switched to the other antiemetic drug for the second chemotherapy cycle (PALO followed by GRA or GRA followed by PALO). The patients could select PALO or GRA antiemetics for the third cycle, according to their preference. A total of 21 patients selected PALO and 18 patients selected GRA in the third cycle, and one patient was withdrawn from the study as their third cycle questionnaire was not obtained. No significant differences between PALO and GRA were identified in first and second cycles. However, during the third cycle, a significant difference was observed in acute‑phase complete control of emetic events between the PALO and GRA groups, which was defined as no emetic episode, no additional antiemetic treatment and no more than mild nausea, between PALO and GRA. These results demonstrated that changing antiemetics may affect the efficacy of antiemetics. This study indicates that alteration of antiemetic regimens, including drug combination and order, may improve the efficacy of antiemetic treatment.

View Figures

View References

1	Ettinger DS, Armstrong DK, Barbour S, et al; National Comprehensive Cancer Network. Antiemesis. J Natl Compr Canc Netw. 10:456–485. 2012.PubMed/NCBI
2	Basch E, Hesketh PJ, Kris MG, Prestrud AA, Temin S and Lyman GH: Antiemetics: american society of clinical oncology clinical practice guideline update. J Oncol Pract. 7:395–398. 2011. View Article : Google Scholar :
3	Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E and Pegoretti B: Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer. 19:823–832. 2011. View Article : Google Scholar
4	Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Thorn MD and Cox D: Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer. 22:469–477. 2014. View Article : Google Scholar :
5	Saito M, Aogi K, Sekine I, et al: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 10:115–124. 2009. View Article : Google Scholar : PubMed/NCBI
6	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
7	Cohen L, de Moor CA, Eisenberg P, Ming EE and Hu H: Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 15:497–503. 2007. View Article : Google Scholar
8	Tonato M, Roila F and Del Favero A: Methodology of antiemetic trials: a review. Ann Oncol. 2:107–114. 1991.PubMed/NCBI
9	Roila F, Tonato M, Basurto C, et al: Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol. 5:141–149. 1987.PubMed/NCBI
10	Sullivan JR, Leyden MJ and Bell R: Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. N Engl J Med. 309:7961983. View Article : Google Scholar : PubMed/NCBI
11	Hesketh PJ: Chemotherapy-induced nausea and vomiting. N Engl J Med. 358:2482–2494. 2008. View Article : Google Scholar : PubMed/NCBI
12	Langford P and Chrisp P: Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting. Core Evid. 5:77–90. 2010. View Article : Google Scholar : PubMed/NCBI
13	Rojas C, Thomas AG, Alt J, et al: Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 626:193–199. 2010. View Article : Google Scholar
14	Hothersall JD, Moffat C and Connolly CN: Prolonged inhibition of 5-HT3 receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization. Br J Pharmacol. 169:1252–1262. 2013. View Article : Google Scholar : PubMed/NCBI
15	Rojas C, Li Y, Zhang J, et al: The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther. 335:362–368. 2010. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Comparison between the antiemetic effects of palonosetron and granisetron in breast cancer patients treated with anthracycline‑based regimens

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles